sellWeak
Neal Pawar sold $483k of ENFN
Chief Operating Officer at Enfusion, Inc.. 48,047 shares at an average of $10.06, traded Dec 2, 2024, filed Dec 4, 2024.
Warning score
38Value
$483k
48,047 shares
Holdings after
1,117,298
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleCOO
- +18Trade size$483k at market
- 0Share of holdings soldSold 4.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-125527, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | SOpen-market sale Class A Common Stock | -21,801 | $10.03 | $219k | 1,143,544 | Dec 4, 2024 |
| Dec 3, 2024 | SOpen-market sale Class A Common Stock | -26,246 | $10.09 | $265k | 1,117,298 | Dec 4, 2024 |
Related signals
Other insiders at Enfusion, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Enfusion, Inc. | Bronwen Bastone Chief People Officer | $36k 3,126 shares | -1% | |
| 51Moderate | Enfusion, Inc. | Oleg Movchan Chief Executive Officer | $130k 11,452 shares | -2% | |
| 30Weak | Enfusion, Inc. | Matthew Campobasso General Counsel | $19k 1,695 shares | -2% | |
| 44Moderate | Enfusion, Inc. | Bradley Herring Chief Financial Officer | $53k 4,645 shares | -1% | |
| 30Weak | Enfusion, Inc. | Valeria Gutowski Chief Accounting Officer | $6,165 542 shares | -1% | |
| 46Moderate | Enfusion, Inc. | Neal Pawar Chief Operating Officer | $166k 14,560 shares | -1% | |
| 30Weak | Enfusion, Inc. | Valeria Gutowski Chief Accounting Officer | $14k 1,233 shares | -2% | |
| 30Weak | Enfusion, Inc. | Bronwen Bastone Chief People Officer | $24k 2,064 shares | -1% | |
| 45Moderate | Enfusion, Inc. | Oleg Movchan Chief Executive Officer | $32k 2,790 shares | -0% | |
| 30Weak | Enfusion, Inc. | Matthew Campobasso General Counsel | $12k 1,081 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.